This study evaluates the performance of the DNA methylation-based Bethesda Classifier v3 (Bv3) for central nervous system (CNS) tumor diagnosis. Bv3 was tested on 516 samples, including straightforward cases and diagnostically challenging cases previously unclassifiable by the Heidelberg Classifier v12.8. It achieved correct classification in 97% of straightforward cases and successfully classified 56% of complex cases, with a low misclassification rate of 4%. The findings suggest that Bv3 is a robust complementary tool for routine neuropathological diagnostics, even for samples with low DNA concentration.
This retrospective study evaluated the diagnostic and prognostic impact of DNA methylation array (MA) profiling in pediatric ependymoma. Out of 63 patients, MA profiling reclassified nearly a quarter of initial diagnoses, with a higher rate before 2019, underscoring the importance of integrated molecular diagnosis. Posterior fossa group A (PFA) ependymoma was the predominant subgroup. Gross total resection was the only factor significantly associated with improved survival, while chromosome 1q gain, exclusively found in PFA patients, was linked to a high relapse rate.
This study investigated pan-TRK expression and NTRK gene aberrations in meningiomas. The findings indicate that pan-TRK expression is common in these tumors, especially in high-grade cases and those with high proliferative activity. While pan-TRK immunohistochemistry may assist in differentiating meningiomas from other central nervous system tumors, NTRK gene aberrations are rare. Therefore, molecular confirmation is crucial to identify patients who could benefit from TRK-targeted therapies.
This single-center retrospective study investigated the prognostic impact of MGMT promoter methylation and TERT promoter mutations in 54 patients with WHO grade 4 glioblastoma. The findings indicate that MGMT methylation is independently associated with improved overall survival, whereas TERT mutations predict worse survival. Adjuvant chemoradiotherapy was also confirmed to improve outcomes. A combined stratification using both biomarkers allows for the identification of four distinct prognostic subgroups, with MGMT-methylated/TERT-wild-type patients exhibiting the longest survival.